表紙:CNS治療薬の世界市場
市場調査レポート
商品コード
997779

CNS治療薬の世界市場

CNS Therapeutics

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 978 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

CNS治療薬の世界市場
出版日: 2021年05月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 978 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のCNS治療薬の市場規模は、2025年には1,377億米ドルに達すると予測されており、神経疾患のアンメットメディカルニーズへの対応に起因しています。

世界において米国と欧州は大きな市場であり、合計で70%のシェアを占めています。また、中国は、社会構造の変化に伴う精神疾患発症リスクの高まりや、神経疾患にまつわる偏見の解消、政府の政策による医療提供体制の整備などの要因に支えられ、分析期間中に7.3%のCAGRとなる見通しで、最も成長率の高い市場となっています。

当レポートは、世界のCNS治療薬市場について調査しており、市場シェア、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • AbbVie Inc.
  • Alkermes Plc.
  • Allergan Plc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Eli Lilly and Co.
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Sanofi
  • Shire Plc
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB Group

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
    • 中枢神経系(CNS)治療薬:序文
    • CNS治療薬のCNS障害の発生率が高まりに伴う強力な機会
    • FDA承認中枢神経系薬のリスト:2019
    • FDA承認中枢神経系薬のリスト:2018
    • 主な医薬品の特許満了による世界の中枢神経系市場への下向きの圧力
    • 主なCNS治療薬の特許満了:2008-2022
    • 優位性を維持するための先進市場
    • 市場の勢いを促進するための市場開発
  • 治療カテゴリー別市場分析
  • 主要企業
  • 動向と推進要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

IV. 競合

  • 企業プロファイル:181社
目次
Product Code: MCP-1835

Abstract:

Global CNS Therapeutics Market to Reach US$144.2 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for CNS Therapeutics estimated at US$103.4 Billion in the year 2020, is projected to reach a revised size of US$144.2 Billion by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027.Pain Management, one of the segments analyzed in the report, is projected to grow at a 5.5% CAGR to reach US$41.4 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anti-Psychotics segment is readjusted to a revised 3.9% CAGR for the next 7-year period. This segment currently accounts for a 14.8% share of the global CNS Therapeutics market.

The U.S. Accounts for Over 27% of Global Market Size in 2020, While China is Forecast to Grow at a 8% CAGR for the Period of 2020-2027

The CNS Therapeutics market in the U.S. is estimated at US$27.9 Billion in the year 2020. The country currently accounts for a 26.98% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$30.6 Billion in the year 2027 trailing a CAGR of 8% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 3.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR while Rest of European market (as defined in the study) will reach US$30.6 Billion by the year 2027.

Anti-Depressants Segment Corners a 11.8% Share in 2020

In the global Anti-Depressants segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$9.2 Billion in the year 2020 will reach a projected size of US$11.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$19.4 Billion by the year 2027, while Latin America will expand at a 3.9% CAGR through the analysis period.

Select Competitors (Total 181 Featured) -

  • AbbVie Inc.
  • Alkermes Plc.
  • Allergan Plc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Eli Lilly and Co.
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Sanofi
  • Shire Plc
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB Group

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Central Nervous System (CNS) Therapeutics: A Prelude
    • CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders
    • List of FDA Approved CNS Drugs: 2019
    • List of FDA Approved CNS Drugs: 2018
    • Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
    • Patent Expiries of Leading CNS Drugs: 2008-2022
    • Developed Markets to Maintain their Dominance
    • Developing Market to Drive the Market Momentum
  • MARKET ANALYSIS BY THERAPEUTIC CATEGORY
    • Anti-Epilepsy Market
    • Global Market Overview
    • Regional Landscape
    • Developed Countries Account for a Major Share of Epilepsy Treatment
    • Developing Countries Struggle with Low Treatment Rates
    • New Approvals (2019 and 2018)
    • Disease Overview
    • EXHIBIT 1: Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
    • EXHIBIT 2: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
    • High Unmet Needs Offer Scope for Market Growth
    • Treatment
    • Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
    • Leading Anti-Epileptic Drugs
    • Leading Anti-Epileptic Drugs and Their Mechanism of Action
    • Patent Expiries of Major Anti-Epilepsy Drugs
    • FDA's New Policy for AED Drugs to Bolster Market Growth
    • AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
    • Select Currently Available Epilepsy Drugs
    • Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
    • Innovative Drugs Needed for Better Treatment Compliance
    • Abounding Potential for NCEs
    • A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
    • FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
    • Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
    • Recent Approvals for Childhood Epilepsy: 2016-2019
    • Review of Anti-Epilepsy Drugs
    • Vimpat®
    • Keppra®
    • Lamictal
    • Tegretol®
    • Sabril®
    • Perampanel
    • Zonegran®
    • Topamax®
    • Trileptal®
    • Neurontin®
    • Lyrica®
    • Depakine®
    • CNS Pain Management
    • Market Overview
    • Treatment
    • Drugs Indicated for Pain Management
    • Select Phase III Ongoing Studies for Cancer Pain
    • Regional Overview
    • Players
    • Combination Therapies Gain Prominence
    • Key Trends in Chronic Pain Management
    • Neuropathic Pain Management: Market with High Potential
    • Select Phase III Ongoing Studies for Neuropathic Pain
    • Lyrica's Generics Gain FDA Approval
    • Migraine Market: A Core Vertical in CNS Pain Management
    • Migraine Care: Select Patent Expiries (2013-2015)
    • Migraine Completed Phase III Studies: As of October 2019
    • Migraine Ongoing Phase III Studies: As of October 2019
    • Select Pain Management Drugs
    • Flupirtine
    • Lyrica
    • Oxycodone
    • Nucynta ER
    • Metabotropic Glutamate Receptors (mGluRs)
    • New Pain Management Drugs
    • Novartis Presents New Data for Aimovig
    • Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
    • Three New Migraine Drugs Obtain FDA Approval
    • Eli Lilly's Emgality Receives FDA Approval
    • Anti-Alzheimer's
    • Market Overview
    • EXHIBIT 3: Global Alzheimer's Prevalence by Age Group
    • Alzheimer's Phase III Completed Studies
    • Alzheimer's Phase III Ongoing Studies
    • Treatment for Alzheimer's
    • Select Leading Drugs for Alzheimer's Disease by Drug Category
    • Patent Expiries of Leading Alzheimer's Drugs
    • Aducanumab Marches towards FDA Approval, Following being Abondoned by Biogen a few Months Ago
    • The Clinical Trials for Aducanumab
    • Aducanumab: A Promising Drug Which would Revolutionalize the Alzheimer's Market
    • Alzheimer's Drugs: A Market Plagued with Failures
    • Promising Compounds with Silver Lining
    • PRI-002 Gains Success in First Stage of Human Testing for Alzheimer's Disease
    • Updated FDA Standards Make Way for Increased Alzheimer's Drug Testing
    • Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
    • Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
    • Elenbecestat's Phase 3 Trials Halted
    • Novel Drug Delivery Method to the Brain Discovered
    • Alzheimer's Association Provides Grant to Longeveron
    • A Review of Select Anti-Alzheimer's Drugs
    • Aricept
    • Exelon
    • Reminyl
    • Ebixa
    • Namenda
    • A Review of the Alzheimer's disease
    • Alzheimer's Effect on Brain
    • Causes for Alzheimer's
    • Who Are at Risk?
    • Prevalence of Alzheimer's Disease
    • Diagnosis of Alzheimer's
    • Anti-Parkinson's
    • Market Overview
    • EXHIBIT 4: Select Top Selling Drugs for Parkinson's Disease
    • Nourianz, An Add-on Medication for Treating Episodes of Parkinson's Disease Secures FDA Approval
    • Recent Approvals
    • Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
    • Xadago - Add-On Therapy for Parkinson's Disease
    • NUPLAZID® - The First and the Only Approved Drug for Psychosis related to Parkinson's disease
    • Parkinson's Phase III Completed Studies: As of October 2019
    • Parkinson's Ongoing Phase III Studies: As of October 2019
    • Select Anti-Parkinson's Drugs
    • Levodopa
    • Dopamine Agonists
    • Mirapex
    • FDA Announces Imminent Discontinuation of Certain Formulations of GSK's Requip for PD and RSL Treatment
    • A Review of the Parkinson's Disease
    • Prevalence
    • Symptoms
    • Causes
    • Diagnosis
    • Anti-Depressants
    • Market Overview
    • EXHIBIT 5: Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
    • Anti-Depressant Treatment
    • EXHIBIT 6: Select Top Selling Anti-Depressants in 2018
    • Select Antidepressants Drugs
    • Zoloft (Sertraline)
    • Cymbalta®
    • Prozac (Fluoxetine)
    • Effexor (Venlafaxine)
    • Paxil
    • Wellbutrin (Bupropion)
    • Recent Approvals of Anti-Depressants
    • Esketamine, the Fast Acting Drug for Depression from Janssen Receives FDA Approval
    • Pipeline Drugs in Phase III for Depressive Disorder: As of October 2019
    • A Review of Depression
    • Prevalence of Depression
    • Causes of Depression
    • Types of Depressive Disorders
    • Available Treatment
    • Tricyclic Antidepressants
    • Monoamine Oxidase Inhibitors
    • Lithium Salts
    • Working of Antidepressants
    • Ranking of Antidepressants in Terms of Efficacy
    • Types of Antidepressants
    • NMDA Receptor Antagonists
    • NMDA Receptor (NMDAR)
    • NMDA Receptor Agonists
    • Acetylcholinesterase Inhibitors
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Workings of SSRIs
    • Safety Levels of SSRI Drugs
    • Adverse Effects of SSRI
    • Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
    • Anti-Psychotics
    • Market Overview
    • Leading Atypical Antipsychotics for the Treatment of Schizophrenia
    • Pipeline Drugs in Phase III for Schizophrenia: As of October 2019
    • Pipeline Drugs in Phase III for Bipolar Disorder: As of October 2019
    • Select Anti-Psychotic Drugs
    • Zyprexa
    • Seroquel
    • Abilify
    • Clozaril
    • Risperdal
    • Risperdal® Consta®
    • Geodon
    • Invega Sustenna
    • Saphris
    • Latuda
    • A Review of Anti-Psychotics
    • Indications of Antipsychotics
    • An Effective Adjunctive Therapy
    • Off-label Uses
    • Efficacy - Marred by Lack of Evidence Base
    • Types of Antipsychotics
    • Difference between Typical and Atypical
    • Atypical Antipsychotics Up Against Typicals
    • Side Effects of Antipsychotics
    • Symptoms of Antipsychotics Withdrawal
    • Bipolar Disorder
    • Symptoms of Bipolar Disorder
    • Mood Episode - A Major Symptom
    • Manic Episode Vs Depressive Episode
    • Causes of Bipolar Disorder
    • Types of Bipolar Disorder
    • Co-morbidities of Bipolar Disorder
    • Schizophrenia
    • Prevalence by Gender
    • Symptoms of Schizophrenia
    • Causes of Schizophrenia
    • Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
    • Multiple Sclerosis (MS)
    • List of Approved Drugs for MS
    • Patent Expiration Date/Year of the Major MS Drugs
    • EXHIBIT 7: Leading Multiple Sclerosis Drugs (2018): Sales in USD Million
    • New Approvals
    • Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
    • Mavenclad Gains FDA Approval
    • Celgene Files NDA for Ozanimod
    • Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
    • Multiple Sclerosis: Pipeline Analysis
    • Pipeline Drugs in Phase III for Multiple Sclerosis: As of October 2019
    • A Review of Multiple Sclerosis (MS)
    • Types of Multiple Sclerosis
    • EXHIBIT 8: Clinical Subtypes of Multiple Sclerosis (MS)
    • Prevalence of MS
    • Causes of MS
    • Myths Surrounding Multiple Sclerosis
    • Symptoms of MS
    • Diagnosis of MS
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Market Overview
    • Approved Drugs for ADHD: 2017
    • Sales of Vyvanse in 2018
    • Pipeline Drugs in Phase III for ADHD: As of October 2019
    • Select ADHD Drugs
    • Vyvanse
    • Concerta
    • Adderall
    • A Review of Attention Deficit Hyperactivity Disorder (ADHD)
    • Consequences of ADHD
    • What Leads to ADHD?
    • Insomnia
    • Overview
    • List of Approved Drugs for Insomnia
    • Pipeline Drugs for Insomnia: As of October 2019
    • Zolpidem
    • Eszopiclone
    • A Review of Insomnia
    • Prevalence of Insomnia
    • Therapies for Insomnia
  • 2. FOCUS ON SELECT PLAYERS
    • AbbVie Inc. (USA)
    • Alkermes Plc. (Ireland)
    • Allergan Plc. (Ireland)
    • AstraZeneca Plc. (UK)
    • BIAL Group (Portugal)
    • Bristol-Myers Squibb (USA)
    • Eisai Co., Ltd. (Japan)
    • Endo Pharmaceuticals Inc. (USA)
    • Eli Lilly and Co. (USA)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Fabre-Kramer Pharmaceuticals, Inc. (USA)
    • GlaxoSmithKline (UK)
    • H. Lundbeck A/S (Denmark)
    • Johnson & Johnson (USA)
    • Janssen Pharmaceuticals, Inc. (USA)
    • Merck & Co., Inc. (USA)
    • Neurocrine Biosciences, Inc. (USA)
    • Novartis AG (Switzerland)
    • Otsuka Pharmaceutical Co., Ltd. (Japan)
    • Pfizer, Inc. (USA)
    • Purdue Pharma L.P. (USA)
    • Sanofi (France)
    • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
    • Sunovion Pharmaceuticals, Inc. (USA)
    • Takeda Pharmaceutical Co., Ltd. (Japan)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • UCB S.A., (Belgium)
  • 3. MARKET TRENDS & DRIVERS
    • Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
    • EXHIBIT 9: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
    • Rising Healthcare Expenditure to Boost CNS Therapeutics Market
    • EXHIBIT 10: World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023
    • EXHIBIT 11: Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
    • Growing Middle Class Population in Emerging Regions to Spur the Market
    • EXHIBIT 12: Global Middle Class Population (In Million) by Region for the Years 2020, 2025 and 2030
    • EXHIBIT 13: Global Middle Class Spending (US$ Trillion) by Region for the Years 2020, 2025, 2030
    • Growing Penetration of Generic Drugs Emerges as a Key Trait
    • EXHIBIT 14: Global Spending on Generic Drugs Vis-a-vis Branded Drugs (2019): Percentage Share Breakdown of Dollar Spending by Drug Category
    • Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
    • Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
    • Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
    • Awareness Campaigns Launched by Pharma Companies to Benefit the Market…
    • Music and Memory Programs Positively Impact Alzheimer's Disease (AD) and Related Dementia (ADRD) Patients
    • New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Pain Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Anti-Psychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Anti-Psychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Anti-Psychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Anti-Depressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Anti-Depressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Anti-Depressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Anti-Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Anti-Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Anti-Epilepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Anti-Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Anti-Alzheimer`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Anti-Alzheimer`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Anti-Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Anti-Parkinson`s by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Anti-Parkinson`s by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Aging Population: A Strong Demographic Driver
    • EXHIBIT 15: North American Elderly Population by Age Group (1975-2050)
    • The Largest CNS Therapeutics Market Globally
    • Patent Expiries of Leading CNS Drugs in the US
    • Focus on Select Markets
    • Alzheimer's Market
    • Anti-depressant Drugs
    • Usage of Antidepressants Surges in the US
    • Anti-Epilepsy Market
    • Epilepsy - A Major Concern for the Healthcare Industry
    • A Glance at Epilepsy Statistics
    • Anti-Epilepsy Drugs
    • The US Epilepsy Market: Patent Expiry of Select Major Drugs
    • Epilepsy in Children
    • Growing Competition from Generics
    • Pain Management Market
    • Consumers in the US Seek Different Options for Chronic Pain Management
    • Neuropathic Pain Market
    • Anti-Psychotic Drugs Market
    • Mental Illnesses - Epidemiology
    • Facts & Figures
    • EXHIBIT 16: Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group
    • Popular Antipsychotic Drugs in the US
    • TABLE 40: The US Anti-Psychotic Drugs Market by Indication (2019E): Percentage Share Breakdown of Value Sales
    • Surging Off-label Prescriptions
    • Generics Occupy Front Seat
    • Rising Antipsychotic Use among Children - A Cause of Concern
    • ADHD Market
    • Select Available ADHD Drugs in the US
    • EXHIBIT 17: The US ADHD Drugs Market by Drug Category (2019E): Market Share Breakdown of Total Prescription Sales for Stimulants (Amphetamines and Methylphenidates) and Non-Stimulants
    • EXHIBIT 18: The US ADHD Drugs Market by Type (2019E): Market Share Breakdown of Total Prescription Sales for Branded & Generic Drugs Groups
    • Adult ADHD Drugs Continue to Widen their Share
    • EXHIBIT 19: The US ADHD Drugs Market by Drug Category (2019E): Percentage Share Breakdown of Total Prescriptions for Adult & Pediatric Patient Groups
    • Market Analytics
    • TABLE 25: USA Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • CANADA
    • CNS Diseases: Facts & Figures
    • TABLE 28: Canada Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 31: Japan Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • CHINA
    • China: The Primary Market for CNS Drugs in Asia-Pacific
    • Select Anti-Schizophrenia Drugs Available in China
    • Other Available CNS Drugs in China
    • TABLE 34: China Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: China Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: China 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • EUROPE
    • European Patent Expiries of Select CNS Drugs
    • Pain Management Market
    • Neuropathic Pain Market Witnesses Foray of Generics
    • Anti-Psychotics Market
    • Demand for Antipsychotics for Bipolar Disorder Upbeat
    • Ageing Population Boosts Demand
    • EXHIBIT 20: 65+ Population as Percentage of Total Population for Major Countries in Europe: As on June 2019
    • TABLE 37: Europe Current & Future Analysis for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 38: Europe Historic Review for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Europe 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 40: Europe Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Europe Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Europe 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 43: France Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: France Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: France 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 46: Germany Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Germany Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Germany 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • ITALY
    • Market Snapshots
    • TABLE 49: Italy Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Italy Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Italy 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • NICE Recommendations on CNS Therapeutics
    • TABLE 52: UK Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: UK Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: UK 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 55: Spain Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Spain Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Spain 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 58: Russia Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Russia Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Russia 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 61: Rest of Europe Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Rest of Europe Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Rest of Europe 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • India & China Offer Significant Growth Opportunities
    • Growing Antipsychotics Market in Asia
    • TABLE 64: Asia-Pacific Current & Future Analysis for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 65: Asia-Pacific Historic Review for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Asia-Pacific 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 67: Asia-Pacific Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Asia-Pacific Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Asia-Pacific 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 70: Australia Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Australia Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Australia 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 73: India Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: India Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: India 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 76: South Korea Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: South Korea Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: South Korea 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 79: Rest of Asia-Pacific Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Rest of Asia-Pacific Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Rest of Asia-Pacific 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 82: Latin America Current & Future Analysis for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 83: Latin America Historic Review for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Latin America 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 85: Latin America Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Latin America Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Latin America 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 88: Argentina Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Argentina Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Argentina 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 91: Brazil Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Brazil Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Brazil 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 94: Mexico Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Mexico Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Mexico 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 97: Rest of Latin America Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of Latin America Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of Latin America 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 100: Middle East Current & Future Analysis for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 101: Middle East Historic Review for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Middle East 15-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 103: Middle East Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Middle East Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Middle East 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 106: Iran Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Iran Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Iran 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 109: Israel Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Israel Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Israel 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 112: Saudi Arabia Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Saudi Arabia Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Saudi Arabia 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 115: UAE Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: UAE Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: UAE 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 118: Rest of Middle East Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Rest of Middle East Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Rest of Middle East 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 121: Africa Current & Future Analysis for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Africa Historic Review for CNS Therapeutics by Segment - Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Africa 15-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Pain Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 181